A medicine containing bioactive peptides and its application in treating cardiovascular and cerebrovascular diseases
By isolating and identifying biologically active peptides with anticoagulant activity from Chuanxiong, combining with polypeptide variants and optimized expression technology, the problem of insufficient types of existing anticoagulant drugs was solved, and effective thrombosis inhibition and blood circulation effects were achieved. Treatment of cardiovascular and cerebrovascular diseases provides new options.
Patent Information
- Application Number
- CN202410257810.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-07
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-03-07
AI Technical Summary
There are not enough types of existing anticoagulants, especially polypeptide drugs. The optional forms provided need to be further enhanced, making it difficult to meet the diverse treatment needs of cardiovascular and cerebrovascular diseases.
Bioactive peptides with anticoagulant activity were isolated and identified from Chuanxiong, and variants of the polypeptide were obtained by conservative or non-conservative amino acid substitution. Combined with optimized expression and delivery techniques, pharmaceutical compositions with anticoagulant activity were prepared.
This biologically active peptide effectively inhibits thrombosis, has good blood-activated properties, and can be prepared as a drug for treating cardiovascular and cerebrovascular diseases. It has good application prospects and significantly improves the anticoagulation effect and safety.
Smart Images

Figure CN118059209B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the biological field, and specifically to a medicine containing a bioactive peptide and its application in treating cardiovascular and cerebrovascular diseases. Background Art
[0002] Cardiovascular and cerebrovascular diseases refer to ischemic or hemorrhagic heart diseases caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc., and are now also called the "three highs" of "rich diseases". The "China Cardiovascular and Cerebrovascular Health and Disease Report 2022" shows that the prevalence and mortality of cardiovascular and cerebrovascular diseases in China are still on the rise. It is estimated that there are 330 million people suffering from cardiovascular and cerebrovascular diseases, including 13 million strokes, 11 million coronary heart disease, 5 million pulmonary heart disease, 8.9 million heart failure, 2.5 million rheumatic heart disease, 2 million congenital heart disease, 45.3 million lower limb artery disease, and 245 million hypertension. As the number one killer of health, cardiovascular and cerebrovascular diseases are threatening the lives and health of 330 million people in my country.
[0003] In the clinical treatment of cardiovascular and cerebrovascular diseases, anticoagulants are mainly used. According to the known coagulation mechanism, the current anticoagulant strategies for inhibiting thrombosis mainly focus on inhibiting thrombin activity, preventing the generation of thrombin, or blocking the initiation of coagulation. New anticoagulants are based on the above pathways, mainly thrombin inhibitors: including direct thrombin inhibitors and indirect thrombin inhibitors; factor Xa, IXa, and VⅡa tissue factor complex inhibitors, which prevent the generation of thrombin; others: including drugs that enhance endogenous anticoagulant pathways or stimulate fibrinolytic activity. In addition, traditional anticoagulants mainly include unfractionated heparin, warfarin, and low molecular weight heparin, etc.
[0004] In clinical applications, unfractionated heparin has the characteristics of rapid onset, poor safety, and low stability of anticoagulant effect. However, it still has good effects in clinical applications. Among them, Wang Yu et al. used low-dose unfractionated heparin in the clinical treatment of primary nephrotic syndrome in children in a clinical study, which significantly improved the patient's urine protein and serum total cholesterol. At the same time, the platelet count and fibrinogen of the children were also significantly improved. The early application of low-dose unfractionated heparin is an important auxiliary means for the clinical treatment of primary nephrotic syndrome in children. It is not only effective, but also has a low incidence of adverse reactions. In a clinical study, Wang Zhiyong et al. made a detailed analysis of the influencing factors of unfractionated heparin treatment of acute cerebral infarction. It was found that patients with older age, low activated partial thromboplastin time value at admission, coronary heart disease, large initial dose of heparin, low triglyceride, low fibrinogen, and no drinking and smoking are more likely to achieve heparinization. At the same time, it is also a single factor that affects the heparinization of unfractionated heparin treatment of acute cerebral infarction. Age and initial dose of heparin have a positive effect on its heparinization, while other factors have a negative effect on heparinization. Low molecular weight heparin is separated from ordinary heparin. Its effect on platelet aggregation function is significantly less than that of ordinary heparin, and the incidence of bleeding complications is low in clinical use. Lin Jianping et al. used ordinary heparin and low molecular weight heparin in high-flux hemodialysis patients, and finally concluded that the dialyzer coagulation and hemostasis time of the two groups of patients were not much different, but the incidence of delayed bleeding in the low molecular weight heparin group was significantly lower than that in the ordinary heparin group. This shows that the application of low molecular weight heparin in hemodialysis patients has higher safety. Zhou Manyun et al. conducted a comparative analysis of the clinical efficacy of ordinary heparin and low molecular weight heparin in the clinical treatment of transient cerebral atrophy, and finally concluded that the clinical treatment effects of low molecular weight heparin and ordinary heparin were not much different, but the bleeding toxicity of low molecular weight heparin was relatively low, so it is more worthy of promotion and application in clinical practice. In the clinic, the effect of low molecular weight heparin on platelets after atrial septal defect closure was analyzed in detail, and it was concluded that the appropriate extension of low molecular weight heparin application time after surgery can appropriately reduce platelet consumption.
[0005] Of course, there have been reports on peptide anticoagulant drugs. Nematode anticoagulant peptides (NAPs) have strong efficacy, long drug half-life, simple and diverse clinical medication methods, and low cost, but the most valuable and promising ones are NAPc2 and NAPS. NAP5 has extremely high anticoagulant activity and can be effective after subcutaneous injection. It has great potential in the treatment of acute platelet-related arterial thrombosis. After binding to FX / Xa, NAPc2 has a high ability to bind to the VIa-TF complex. Because NAPc2 has a long biological half-life (up to 50 hours or more for subcutaneous or intravenous injection), it can be used once every 1-2 days, and after subcutaneous injection, it shows high biological activity.
[0006] At present, there are not enough types of anticoagulant drugs, especially peptide drugs, and the available options need to be further enhanced. Summary of the invention
[0007] The present invention provides a bioactive peptide which can be used for treating cardiovascular and cerebrovascular diseases.
[0008] Specifically, the bioactive peptides of the present invention are isolated from Ligusticum chuanxiong.
[0009] Chuanxiong is the rhizome of the perennial herbaceous plant Chuanxiong of the Umbelliferae family. It is pungent and warm and enters the liver, gallbladder, and pericardium meridians, promoting blood circulation and qi, dispelling wind and relieving pain. It has the effects of promoting blood circulation and qi, dispelling wind and relieving pain, and is a commonly used traditional Chinese medicine for promoting blood circulation and removing blood stasis. It is mainly used to treat irregular menstruation, amenorrhea, dysmenorrhea, abdominal pain due to symptom, stabbing pain in the chest and ribs, swelling and pain due to falls, headache, and rheumatic pain. Chuanxiong contains a variety of compounds such as various lactones, alkaloids, phenols, and volatile oils. The inventor found through research that a bioactive peptide with good anticoagulant activity was isolated and identified for the first time in Chuanxiong.
[0010] The amino acid sequence of the bioactive peptide is shown in SEQ ID NO:1.
[0011] Specifically, variants of the polypeptides of the present invention are also provided, which include sequences in which one or more amino acid residues (e.g., one or more amino acid residues of the exemplary polypeptides of the present invention) are replaced by conservative or non-conservative amino acid residues (e.g., conservative amino acid residues), such substituted amino acid residues may be amino acids encoded by the genetic code or not encoded by it. Conservative substitutions are those in which a given amino acid in a polypeptide is replaced by another amino acid having similar properties. Therefore, the polypeptides of the present invention include those polypeptides having conservative substitutions of the sequences of the present invention, such as the exemplary polypeptides of the present invention, and the substitutions include but are not limited to the following substitutions: substitution of aliphatic amino acids such as alanine, valine, leucine and isoleucine with another aliphatic amino acid; substitution of serine with threonine, or substitution of threonine with serine; substitution of acidic residues such as aspartic acid and glutamic acid with another acidic residue; substitution of residues having an amide gene, such as asparagine and glutamine with another residue having an amide gene; exchange of basic residues such as lysine and arginine with another basic residue; substitution of aromatic residues such as phenylalanine and tyrosine with another aromatic residue. Other variants are those that contain substitution groups in one or more of the amino acid residues of the polypeptides of the invention.
[0012] Furthermore, the polypeptide of the present invention can be recombinantly expressed or artificially synthesized.
[0013] Host cells for expressing nucleic acids, expression cassettes and vectors of the present invention include bacteria, yeast, fungi, plant cells, insect cells and mammalian cells. Therefore, the present invention provides methods for optimizing codon usage in all these cells, nucleic acids in which codons are changed, and polypeptides encoded by nucleic acids in which codons are changed. Typical host cells include Gram-negative bacteria, such as Escherichia coli and Pseudomonas fluorescens; Gram-positive bacteria, such as Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lactococcus cremoris, Bacillus subtilis. Exemplary host cells also include eukaryotic organisms, such as various yeasts, such as Saccharomyces sp., including Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris and Kluyveromyces lactis, Hansenula polymorpha, Aspergillus niger and mammalian cells and cell lines and insect cells and cell lines. Therefore, the present invention also includes nucleic acids and polypeptides optimized for expression in these organisms and species. For example, the codons of a nucleic acid encoding a polypeptide isolated from a bacterial cell are modified so that the nucleic acid is optimally expressed in a cell different from the bacterium from which the polypeptide was obtained, such as a yeast, fungus, plant cell, insect cell or mammalian cell. Methods for optimizing codons are known in the art.
[0014] The present invention further provides a pharmaceutical composition having anticoagulant activity, which contains the amino acid sequence of the bioactive peptide of the present invention as shown in SEQ ID NO:1.
[0015] Furthermore, the present invention further provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, which contains the amino acid sequence of the bioactive peptide of the present invention as shown in SEQ ID NO:1.
[0016] Furthermore, the pharmaceutical composition of the present invention also contains a pharmaceutically acceptable carrier.
[0017] Carrier refers to a substance that usually constitutes the major part of a composition or dosage form. Suitable carriers include celluloses such as microcrystalline cellulose; sugars such as lactose, sucrose, mannitol and sorbitol; and starches such as those derived from wheat, corn, rice and potatoes. The amount of the carrier in the formulation may be from about 10 to about 90% by weight of the total formulation, or from about 25 to about 75% by weight, or from about 30 to about 60% by weight, or from about 12 to about 60% by weight. In one embodiment, the carrier is microcrystalline cellulose. Binder refers to a substance that binds or "glue" the powders together and makes the powders cohesive by forming granules, thus acting as "stickiness" in the formulation. Binders increase the cohesion of the diluent or filler used. Suitable binders include sugars such as lactose, sucrose and corn sweeteners; starches derived from wheat, corn, rice and potatoes; natural gums such as gum arabic, gelatin and tragacanth; seaweed derivatives such as alginic acid, sodium alginate and calcium ammonium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose, and hydroxypropyl methylcellulose; polyvinyl pyrrolidone; polyethylene glycol; waxes and inorganic substances such as magnesium aluminum silicate. The amount in the binder formulation can be about 10 to about 90% by weight of the total formulation, or about 25 to about 75% by weight, or about 30 to about 60% by weight, or about 12 to about 60% by weight. In one embodiment, the binder is anhydrous lactose.
[0018] The polypeptide pharmaceutical compositions described in detail herein are formulated for any available delivery route, including oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., intramuscular, subcutaneous, or intravenous), topical, or transdermal delivery forms. The polypeptide or its salt can be formulated with a suitable carrier to provide a delivery form, including but not limited to tablets, caplets, capsules (e.g., hard gelatin capsules or soft elastic gelatin capsules), cachets, lozenges, lozenges, gums, dispersions, suppositories, ointments, cataplasms (mud compresses), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and elixirs.
[0019] Furthermore, the pharmaceutical composition of the present invention further contains a surfactant.
[0020] As used herein, "surfactant" refers to an adjuvant substance that reduces the contact angle between the active pharmaceutical ingredient and the environment in which it is used in a mammal, and may also be referred to as a wetting agent. Treatment of diseases (such as HCV) that require high doses of the compounds of the present invention can be enhanced by increasing the absorption rate of the compounds and thereby increasing the degree of absorption of the compounds in mammals. The surfactant in the pharmaceutical preparation of the present invention will enhance the wettability of the compounds of the present invention for aqueous systems (e.g., in mammals) and increase the dissolution rate of the compounds, allowing a greater amount of the compounds to be absorbed and utilized compared to the preparations of the compounds of the present invention that do not contain surfactants. Any pharmaceutically acceptable surfactant that enhances the wettability of the compounds of the present invention can be used. Particularly suitable surfactants include sodium lauryl sulfate, stearic acid, monoethanolamine, sodium docusate, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, ethoxylated aliphatic alcohols, propylene glycol monocaprylate, glyceryl monostearate, medium chain triglycerides, polyoxyethylene alkyl ethers, and polyoxyethylene stearate. In one embodiment, the surfactant is sodium lauryl sulfate. In another embodiment, the surfactant is a polyoxyethylene sorbitan fatty acid ester. In yet another embodiment, the surfactant is PEG-1-PEG-9-lauryl glycol ether. These surfactants can be used in the pharmaceutical preparations of the present invention alone or in combination in a total amount of about 0.1 to about 10 wt % or about 1 to about 5 wt %.
[0021] The pharmaceutical composition of the present invention also contains an acidulant. The acidulant refers to an adjuvant substance that reduces the pH of the formulation. Acidic pH environments can improve the stability of the compounds of the present invention. Any pharmaceutically acceptable acidulant that can improve the stability of the compounds of the present invention can be used. Particularly suitable acidulants include tartaric acid, ascorbic acid, citric acid, malic acid, and succinic acid. In one embodiment, the acidulant is tartaric acid. These acidulants can be used in the pharmaceutical formulation of the present invention in a total amount of about 0.1 to about 10 weight % or about 1 to about 5 weight %, alone or in combination.
[0022] The pharmaceutical composition of the present invention also contains a glidant. A glidant refers to a substance that prevents agglomeration and improves the flow characteristics of the particles so that the flow is uniform and smooth. Suitable glidants include silicon dioxide and talc. The amount of the glidant in the formulation can be about 0.1 to about 5% by weight or about 0.5 to about 3% by weight of the total formulation. A lubricant is a substance added to the dosage form to enable tablets, particles, etc. to be released from a mold or die after they are compressed by reducing friction or wear. Suitable lubricants include metal stearates, such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water-soluble lubricants, such as sodium borate chloride, sodium benzoate, sodium acetate, sodium chloride sodium oleate, polyethylene glycol and d'l-leucine. Lubricants are often added in the last step before compression because they must be present on the surface of the particles and between the particles and the tablet press accessories. The lubricant may be present in the formulation in an amount of about 0.1 to about 10% or about 0.5 to about 5% by weight of the formulation.
[0023] The pharmaceutical compositions of the present invention also contain a disintegrant. A disintegrant is a substance added to a formulation to aid in its rupture (disintegration) and release of the drug. Suitable disintegrants include starch; "cold water soluble" modified starches, such as sodium starch glycolate; natural and synthetic gums, such as locust bean, karaya, guar, tragacanth, and agar; cellulose derivatives, such as methylcellulose and sodium carboxymethylcellulose; microcrystalline cellulose and cross-linked microcrystalline cellulose, such as cross-linked sodium carboxymethylcellulose; alginates, such as alginic acid and sodium alginate; clays, such as bentonite; and effervescent mixtures. The amount of disintegrant in the composition may be from about 2 to about 15% by weight or from about 2 to about 10% by weight of the formulation.
[0024] The polypeptides described herein are prepared as pharmaceutical preparations.
[0025] For oral tablets), the carrier can be in various forms. In addition, the pharmaceutical preparation may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators and salts, buffers, coatings or antioxidants for regulating osmotic pressure. The preparation comprising the polypeptide may also contain other substances with valuable therapeutic properties. The pharmaceutical preparation can be prepared by known pharmaceutical methods. The polypeptides described in detail herein can be applied to individuals in the form of generally accepted oral compositions, such as tablets, coated tablets and hard or soft shell gel capsules, emulsions or suspensions. Examples of carriers that can be used to prepare these compositions are lactose, corn starch or its derivatives, talcum powder, stearate or its salts, etc. Acceptable carriers for gel capsules with soft shells are, for example, vegetable oils, waxes, fats, semisolid and liquid polyols, etc. In addition, the pharmaceutical preparation may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators and salts, buffers, coatings or antioxidants for regulating osmotic pressure.
[0026] The polypeptide or composition provided herein can be applied to an individual for a desired time period or duration according to an effective dosing regimen, for example, at least about one month, at least about 2 months, at least about 3 months, at least about 6 months or at least about 12 months or longer, which can last for the duration of an individual's life in some variations. In one embodiment, the polypeptide is applied daily or intermittently. The polypeptide can be applied to an individual continuously (e.g., at least once a day) for a period of time. The frequency of administration can also be less than once a day, such as approximately once a week. The frequency of administration can be more than once a day, such as twice or three times a day. The frequency of administration can also be intermittent, including a "drug holiday" (e.g., once a day for 7 days, then no administration for 7 days, repeated in any 14-day time period, such as about 2 months, about 4 months, about 6 months or longer time period). Any frequency of administration can be used with any polypeptide described herein in conjunction with any dosage described herein.
[0027] Beneficial Effects
[0028] The present invention separates and prepares bioactive peptides with good anticoagulant activity from Chuanxiong, the active peptides can effectively inhibit the formation of thrombus and have good blood circulation properties, can be prepared into medicines for treating cardiovascular and cerebrovascular diseases, and have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 Effect of C-7-3-b anticoagulant peptide on coagulation time of mice
[0030] Figure 2 Effects of peptides on thrombosis DETAILED DESCRIPTION
[0031] The specific embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although the specific embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to enable the scope of the present invention to be fully communicated to those skilled in the art.
[0032] Example 1 Isolation and preparation of anticoagulant polypeptide from Chuanxiong
[0033] Take fresh rhizome of Chuanxiong, slice it and freeze-dry it, crush the freeze-dried rhizome, extract protein with stirring at 40℃ with a PBS solution ratio of 1:15, adjust the pH of the extract to 8.0 with 1M NaOH solution, extract for 2h, centrifuge the extract at 4000rpm, repeat the extraction of precipitation, add 1M HCI solution to the supernatant until the precipitation no longer increases, centrifuge at 4000rpm and discard the supernatant, combine the precipitation, freeze-dry, obtain rhizome protein powder of Chuanxiong, and store it at 4℃ for later use. Prepare a protein solution with a mass concentration of 3%, use flavor protease at pH7.0 and 50℃, add 2500U / g of enzyme, and continue enzymolysis for 5h, heat the sample at 90℃ for 10min to terminate the enzymolysis reaction, centrifuge at 8000r / min for 10min to take the supernatant.
[0034] The mass concentration of the supernatant protein was adjusted to 15 g / L, and the supernatant was separated by Sephadex G-50 column chromatography, loaded, eluted with deionized water, and the flow rate was 2 mL / min. The components with similar absorbance were collected and mixed, and a total of 13 important components were collected. The conventional APTT anticoagulant efficacy test in this field (see: Study on the in vitro anticoagulant activity of leech ethanol extract) was used to determine the anticoagulant effect of the components, and it was found that the C-7 component had anticoagulant activity. The Sephadex G-25 column chromatography was continued to separate, and the C-7 component was concentrated to 15% of the volume, filtered with a 0.8 μm microporous filter membrane, loaded, eluted with deionized water, and the flow rate was 2 mL / min. The components were collected, and the APTT anticoagulant efficacy test was continued to determine the anticoagulant effect of the components, and it was found that the C-7-3 component had good anticoagulant activity. The C-7-3 component was filtered through a 0.8 μm microporous filter membrane and loaded. Eluted with 10% methanol, flow rate 1mL / min, connected to HD-3 UV detector, online detection, detection wavelength 280nm, BSZ-100 automatic fraction collector to collect fractions, each tube collection 10min, recorder online record absorbance, paper speed 2cm / h. The results showed that after separation by C18 reverse phase column, C-7-3 component was separated into 3 components, 10μL of sample solution was taken, and thromboplastin time (APTT) reagent was added according to the kit instructions, and the APTT value was determined by platelet aggregation coagulation factor analyzer, and the results are shown in Table 1.
[0035] Table 1 APTT anticoagulant efficacy results of each component
[0036] ;
[0037] #Compared with normal saline, P<0.05.
[0038] As can be seen from Table 1, the C-7-3-b component has a good anticoagulant effect. Therefore, the C-7-3-b component with good activity was subjected to mass spectrometry analysis to obtain the amino acid sequence of the C-7-3-b component polypeptide as shown in SEQ ID NO: 1. The polypeptide was commissioned for artificial synthesis and used as a standby.
[0039] Example 2 Identification of biological activity of C-7-3-b anticoagulant polypeptide
[0040] The third generation of well-grown human umbilical vein endothelial cells (HUVEC (SV40) cell number: SNL-503, Shanen Biotech) were used for the experiment.
[0041] Preparation of endothelial cell injury model: When HUVECs grew to a monolayer cell confluence of more than 80%, they were digested to prepare a single cell suspension and the cell density was adjusted to 2.0x10 5 L -1, inoculated in a 24-well culture plate. Add 200 μL of cell suspension to each well of the 24-well plate, and prepare the hypoxia model on the third day. Aspirate the culture medium in the plate, rinse with PBS, add culture medium without fetal bovine serum, place in a homemade closed hypoxia tank, and continuously introduce mixed gas (95% N 2 , 5%CO 2 )3L / min, replace the oxygen in the container. When the oxygen content in the container is lower than 1%, stop ventilation and place in a 37℃ incubator for 12h to form an oxygen-deficient model. Collect the supernatant in full and centrifuge at 10000g for 3min to remove cell debris and place in -20℃ for later use. The experiment was randomly divided into: (1) Normal control group: replace the culture medium without fetal bovine serum (2ml), place in 37℃, volume fraction 95%0 2 -5%C0 2 Incubator for 12 hours. (2) Hypoxia model group: The conditions were the same as those of the normal control group, except that the oxygen content was replaced by mixed gas. (3) Peptide intervention group: divided into 4 subgroups, the culture medium containing C-7-3-b peptide was replaced, and the final concentration of C-7-3-b peptide in the culture medium was 1, 10, 50 and 100 mg / L, respectively. Hypoxia treatment was performed after 1 hour of normal culture, with 8 wells in each group. The number of floating cells in each group was observed and counted, and the culture medium of each group was taken to determine 6-keto-PGF1α by radioimmunoassay. The specific operation was carried out according to the instructions of the kit. The results are shown in Table 2.
[0042] Table 2 Number of floating cells and 6-keto-PGF1α levels in the cell supernatant of each group
[0043] ;
[0044] As can be seen from Table 2, compared with the control group, the number of floating cells in the model group increased significantly (P<0.01), and after treatment with different concentrations of polypeptides, the number of floating cells decreased significantly relative to the model group (P<0.01), and had a dose-dependent effect. The 6-keto-PGF1α in the hypoxia model group was significantly lower than that in the normal control group (P<0.01), and the expression level of 6-keto-PGF1α was significantly improved after polypeptide treatment (P<0.05). It can be seen that when HUVEC cells are damaged by hypoxia, some of its functions will be affected, and eventually it will become necrotic and float. This study shows that compared with the control group, the number of floating cells in the culture medium of the VEC hypoxia injury model increased significantly, and the anticoagulant factor 6-keto-PGF1α decreased significantly. The polypeptide can significantly reduce the number of floating cells and increase the level of 6-keto-PGF1α, thereby having an anticoagulant effect. This shows that the polypeptide of the present invention can be used to treat embolic cardiovascular and cerebrovascular diseases.
[0045] Example 3 Animal Experiment on C-7-3-b Anticoagulant Peptide
[0046] Fifty mice were randomly divided into five groups, with 10 mice in each group. Three groups were injected with high (100 μg / kg), medium (50 μg / kg), and low doses (10 μg / kg) of C-7-3-b polypeptide injection via tail vein once a day. A normal saline control group and a positive control recombinant hirudin (100 μg / kg) group were also set up. The recombinant hirudin was purchased from prospec, item number: PRO-362. The injection was continued for 3 days. One hour after administration on the fourth day, blood was collected from the retrobulbar venous plexus in the mouse eyes. The coagulation time of each group of mice was measured by capillary tube method. The results are shown in Figure 1 shown.
[0047] Depend on Figure 1 The results show that after the polypeptide group and the positive control group were injected into mice, their coagulation time was significantly prolonged compared with the saline group, and the comparison between each group and the saline group showed that P<0.05. This shows that the polypeptide of the present invention can significantly increase the coagulation time of mice, and compared with the positive control group, at the same concentration, it has a better anticoagulant effect.
[0048] In addition, 1 mg / mL of epinephrine hydrochloride was diluted 1-fold with normal saline, and 0.2 mL of the diluted epinephrine hydrochloride was injected subcutaneously every 4 hours on the first day for a total of 3 times. In the middle of each two administrations, the rats were placed in 0℃ ice water for 4 minutes for two cold stimulations. On the second day, epinephrine was still given twice according to the previous day's dose (4 hours apart), and in the middle of the two administrations, the rats were placed in ice water for 3 minutes for a cold stimulation.
[0049] In vitro antithrombotic test: The mice were randomly divided into 6 groups, 10 mice in each group. After modeling, the 3 groups were given C-7-3-b polypeptide injection at high (100 μg / kg), medium (50 μg / kg), and low doses (10 μg / kg). Physiological saline was used as a blank control, recombinant hirudin (100 μg / kg) was used as a positive control, and an equal volume of physiological saline was given as a model control after modeling. The jugular vein was administered, and blood was collected from the inferior vena cava 30 minutes later. The first few drops of blood were discarded, and 1.8 mL of blood was taken into a polyethylene tube. It was placed on the ring of the in vitro thrombosis instrument for rotation within 1 minute. After 10 minutes, it was poured out and spread on filter paper to absorb the residual blood; its length was measured, its wet weight was weighed, and then it was placed in a glass dish and dried in an oven at 65°C for 30 minutes. It was taken out and its dry weight was weighed to calculate the in vitro thrombosis inhibition rate. Inhibition rate = [wet weight (mg) - dry weight (mg)] / wet weight (mg) × 100%, see Figure 2 shown.
[0050] Depend on Figure 2The results showed that the thrombus inhibition rate of the model control group was significantly lower than that of the blank control group, so the model was successfully established. The thrombus inhibition rate of the polypeptide treatment group (low, medium, and high doses) and the positive control group was significantly higher than that of the model control group, and the difference between each group and the model control group was significant (P<0.05), which showed that the polypeptide of the present invention can significantly improve the thrombus inhibition rate of rats and has a good anti-thrombotic effect. It can be used to treat cerebrovascular-related diseases.
[0051] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. Although embodiments of the present invention have been shown and described, those skilled in the art will appreciate that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purpose of the present invention, and that the scope of the present invention is defined by the claims and their equivalents.
Claims
1. A bioactive peptide with anticoagulant activity for treating cardiovascular and cerebrovascular diseases, characterized in that The amino acid sequence is shown in SEQ ID NO:
1.
2. Use of the bioactive peptide according to claim 1 in the preparation of anticoagulant drugs for treating cardiovascular and cerebrovascular diseases.
3. The use according to claim 2, wherein the medicine contains a pharmaceutically acceptable carrier.
4. The use according to claim 3, characterized in that The carrier comprises an excipient, and the excipient is starch.
